Status:
COMPLETED
Efficacy of T2259 in DED
Lead Sponsor:
Laboratoires Thea
Conditions:
Dry Eye Syndromes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to compare the performance and safety of T2259 versus Vismed Multi in dry eye patients with superficial keratitis.
Eligibility Criteria
Inclusion
- Main inclusion Criteria:
- Signed and dated informed consent
- Male or female aged from ≥ 18 years old
- Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection
- Main exclusion Criteria:
- Far best-corrected visual acuity≤2/10
- Severe Blepharitis
Exclusion
Key Trial Info
Start Date :
April 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2021
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT03874429
Start Date
April 24 2019
End Date
March 25 2021
Last Update
November 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
C.H.N.O des XV-XX
Paris, France, 75012